CL2017003436A1 - Compuestos de benzoxacepina oxazolidinona y métodos de uso - Google Patents

Compuestos de benzoxacepina oxazolidinona y métodos de uso

Info

Publication number
CL2017003436A1
CL2017003436A1 CL2017003436A CL2017003436A CL2017003436A1 CL 2017003436 A1 CL2017003436 A1 CL 2017003436A1 CL 2017003436 A CL2017003436 A CL 2017003436A CL 2017003436 A CL2017003436 A CL 2017003436A CL 2017003436 A1 CL2017003436 A1 CL 2017003436A1
Authority
CL
Chile
Prior art keywords
methods
pi3k
benzoxacepin
oxazolidinone compounds
compounds
Prior art date
Application number
CL2017003436A
Other languages
English (en)
Inventor
Marie-Gabrielle Braun
Richard Elliott
Emily Hanan
Robert Andrew Heald
Calum Macleod
Steven T Staben
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017003436A1 publication Critical patent/CL2017003436A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>EN EL PRESENTE DOCUMENTO SE DESCRIBEN COMPUESTOS DE BENZOXACEOINA OXAZOLIDINONA CON ACTIVIDAD O FUNCIÓN MODULADORA DE FOSFOINOSITIDO 3 CINASA (PI3K) QUE TIENEN LA ESTRUCTURA DE FÓRMULA 1, O ESTEREOISÓMEROS, TAUTÓMEROS, O SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, Y CON LOS SUSTITUYENTES Y CARACTERÍSTICAS ESTRUCTURALES DESCRITAS EN EL PRESENTE DOCUMENTO. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS Y MEDICAMENTOS QUE INCLUYEN LOS COMPUESTOS DE FÓRMULA 1, ASÍ COMO MÉTODOS PARA USAR DICHOS MODULADORES DE PI3K, SOLOS O EN COMBINACIÓN CON OTROS AGENTES TERAPÉUTICOS, PARA TRATAR ENFERMEDADES O AFECCIONES QUE ESTÁN MEDIADAS O QUE SON DEPENDIENTES DE LA DESREGULACIÓN DE PI3K.</p>
CL2017003436A 2015-07-02 2017-12-28 Compuestos de benzoxacepina oxazolidinona y métodos de uso CL2017003436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562188029P 2015-07-02 2015-07-02

Publications (1)

Publication Number Publication Date
CL2017003436A1 true CL2017003436A1 (es) 2018-05-04

Family

ID=56292756

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003436A CL2017003436A1 (es) 2015-07-02 2017-12-28 Compuestos de benzoxacepina oxazolidinona y métodos de uso

Country Status (35)

Country Link
US (8) US9650393B2 (es)
EP (6) EP3567045B1 (es)
JP (4) JP6523490B2 (es)
KR (2) KR102014326B1 (es)
CN (4) CN111909173B (es)
AR (1) AR105238A1 (es)
AU (2) AU2016287463B2 (es)
CA (1) CA2982708C (es)
CL (1) CL2017003436A1 (es)
CO (1) CO2017011038A2 (es)
CR (1) CR20170563A (es)
DK (1) DK3317284T3 (es)
ES (2) ES2908300T3 (es)
FI (1) FIC20253008I1 (es)
FR (1) FR25C1039I2 (es)
HR (1) HRP20192349T1 (es)
HU (2) HUE046756T2 (es)
IL (3) IL255200B (es)
LT (2) LT3317284T (es)
MA (3) MA49861A (es)
MX (2) MX388533B (es)
MY (1) MY195002A (es)
NL (1) NL301344I2 (es)
NO (1) NO2025044I1 (es)
PE (2) PE20181021A1 (es)
PH (2) PH12017502425A1 (es)
PL (2) PL3567045T3 (es)
PT (1) PT3317284T (es)
RS (1) RS59740B1 (es)
SG (1) SG10201913980SA (es)
SI (1) SI3317284T1 (es)
TW (4) TWI649326B (es)
UA (1) UA121678C2 (es)
WO (1) WO2017001645A1 (es)
ZA (2) ZA201808370B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
JP6522807B2 (ja) 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
US10065970B2 (en) 2015-09-08 2018-09-04 Genentech, Inc. Tricyclic PI3K inhibitor compounds and methods of use
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
PL3851441T3 (pl) * 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
IL298518B2 (en) * 2017-04-28 2025-05-01 Hoffmann La Roche Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation
EP3781571B1 (en) 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
AU2019276514B2 (en) * 2018-05-30 2023-12-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
KR20210035211A (ko) * 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
EP3863618A1 (en) 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin
CN109265408B (zh) * 2018-12-11 2020-09-01 上海皓元生物医药科技有限公司 二氟甲基取代噁烷-2-酮的合成方法
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN111995541B (zh) * 2019-05-27 2025-05-06 君实润佳(上海)医药科技有限公司 含有稳定重同位素的酰胺官能团的化合物及其应用
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2021088845A1 (zh) * 2019-11-04 2021-05-14 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
CN113227101B (zh) * 2019-11-25 2024-10-11 上海翰森生物医药科技有限公司 含三并环类衍生物的盐或晶型及其药物组合物
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
MX2022006566A (es) * 2019-12-03 2022-07-01 Genentech Inc Tratamientos conjuntos para tratamiento de cancer de mama.
MX2023006793A (es) * 2020-12-11 2023-06-20 Genentech Inc Tratamientos conjuntos para tratamiento de cancer her2.
WO2022161347A1 (zh) * 2021-01-29 2022-08-04 南京明德新药研发有限公司 三并环类化合物及其应用
EP4294395B1 (en) 2021-02-16 2025-03-26 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
AU2022275275A1 (en) 2021-05-13 2023-12-14 Betta Pharmaceuticals Co., Ltd Polymorph of imidazolidinone compound, preparation method therefor and use thereof
KR20240013791A (ko) * 2021-05-28 2024-01-30 제넨테크, 인크. 벤족사제핀 옥사졸리디논 화합물을 제조하기 위한 공정
WO2023002988A1 (ja) 2021-07-19 2023-01-26 京セラ株式会社 通信方法
MA63885B1 (fr) * 2021-08-09 2025-01-31 Scorpion Therapeutics, Inc. Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer
PL4504202T3 (pl) 2022-04-06 2026-05-04 Genentech Inc. Terapie skojarzone do leczenia raka obejmujące GDC-6036 i GDC-0077
WO2024022435A1 (zh) * 2022-07-27 2024-02-01 南京明德新药研发有限公司 一种5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英化合物的晶型及其制备方法
JP2025539034A (ja) 2022-11-11 2025-12-03 アストラゼネカ・アクチエボラーグ 癌の治療のための併用療法
TW202440096A (zh) 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案
KR20260049827A (ko) 2023-08-11 2026-04-14 에프. 호프만-라 로슈 아게 코팅 정제를 포함하는 약학적 제제
WO2025122470A1 (en) 2023-12-04 2025-06-12 Genentech, Inc. Combination therapies for treatment of breast cancer
CN122295128A (zh) 2023-12-05 2026-06-26 基因泰克公司 用于治疗her2癌症的组合疗法
WO2025181153A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors
WO2026161536A1 (en) 2025-01-24 2026-07-30 Genentech, Inc. Combination therapies for use in the treatment of breast cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
DE60144277D1 (de) 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
BRPI0417749A (pt) 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
GB0610866D0 (en) 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20081679A1 (es) 2006-12-07 2008-12-18 Hoffmann La Roche Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso
JP5529746B2 (ja) * 2007-11-21 2014-06-25 デコード ジェネティクス イーエイチエフ 炎症性疾患、心臓血管疾患及び中枢神経系障害を治療するための置換されたベンゾアゾールｐｄｅ４阻害剤
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
TWI423980B (zh) * 2009-09-28 2014-01-21 Hoffmann La Roche 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法
US8263633B2 (en) * 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
US20120231015A1 (en) * 2009-11-06 2012-09-13 Emory University Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
KR20140032383A (ko) * 2011-03-21 2014-03-14 에프. 호프만-라 로슈 아게 Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법
NO3175985T3 (es) 2011-07-01 2018-04-28
US9271988B2 (en) 2011-07-01 2016-03-01 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer
UY34632A (es) * 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
US9751153B2 (en) * 2012-03-30 2017-09-05 Brigham Young University Effort modulation for process control of friction stir operations
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
US9303043B2 (en) * 2013-03-13 2016-04-05 Greentech, Inc. Process for making benzoxazepin compounds
JP6260967B2 (ja) * 2013-11-06 2018-01-17 国立大学法人京都大学 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
JP6522807B2 (ja) 2015-07-02 2019-05-29 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
PL3851441T3 (pl) 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
IL298518B2 (en) * 2017-04-28 2025-05-01 Hoffmann La Roche Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation
KR20210035211A (ko) 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
EP3863618A1 (en) 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin
MX2022006566A (es) 2019-12-03 2022-07-01 Genentech Inc Tratamientos conjuntos para tratamiento de cancer de mama.

Also Published As

Publication number Publication date
HUE046756T2 (hu) 2020-03-30
KR20190100432A (ko) 2019-08-28
US20240199594A1 (en) 2024-06-20
RU2018103454A3 (es) 2019-11-21
BR112017023121A2 (pt) 2018-07-10
IL255200B (en) 2020-05-31
TWI649326B (zh) 2019-02-01
CR20170563A (es) 2018-02-20
JP2018519307A (ja) 2018-07-19
CA2982708C (en) 2023-10-03
NZ736222A (en) 2024-05-31
LTPA2025536I1 (es) 2025-10-10
JP6523490B2 (ja) 2019-06-05
US20250326745A1 (en) 2025-10-23
CA2982708A1 (en) 2017-01-05
US20170015678A1 (en) 2017-01-19
TW201815798A (zh) 2018-05-01
US11760753B2 (en) 2023-09-19
EP4212536B1 (en) 2025-02-19
IL272277A (en) 2020-02-27
JP6880101B2 (ja) 2021-06-02
KR20180006460A (ko) 2018-01-17
ZA201808370B (en) 2023-03-29
EP4696380A3 (en) 2026-04-29
HUS2500040I1 (hu) 2025-10-28
TWI601732B (zh) 2017-10-11
NL301344I2 (nl) 2025-11-10
AU2016287463B2 (en) 2020-07-02
US9650393B2 (en) 2017-05-16
EP3567045A1 (en) 2019-11-13
JP2021119144A (ja) 2021-08-12
MX372624B (es) 2020-05-07
MX388533B (es) 2025-03-20
WO2017001645A1 (en) 2017-01-05
FR25C1039I1 (fr) 2025-11-21
RU2730529C2 (ru) 2020-08-24
EP3778607B1 (en) 2023-08-30
PL3317284T3 (pl) 2020-04-30
MY195002A (en) 2022-12-30
RS59740B1 (sr) 2020-02-28
EP3778607C0 (en) 2023-08-30
PT3317284T (pt) 2020-01-10
ZA202500997B (en) 2025-10-29
CN112047960A (zh) 2020-12-08
NO2025044I1 (no) 2025-09-23
AU2020204418B2 (en) 2022-02-03
CN111909173B (zh) 2025-03-04
MA42295B1 (fr) 2020-02-28
LT3317284T (lt) 2020-01-27
FR25C1039I2 (fr) 2026-06-05
EP3567045B1 (en) 2022-01-12
US20250197386A1 (en) 2025-06-19
ES2908300T3 (es) 2022-04-28
US20170210733A1 (en) 2017-07-27
IL255200A0 (en) 2017-12-31
KR102306071B1 (ko) 2021-10-01
EP4212536C0 (en) 2025-02-19
JP2023103242A (ja) 2023-07-26
MX2020003415A (es) 2021-12-07
TW201936612A (zh) 2019-09-16
SG10201913980SA (en) 2020-03-30
EP4696380A2 (en) 2026-02-18
EP4212536A1 (en) 2023-07-19
MA54252A (fr) 2022-04-27
US10112932B2 (en) 2018-10-30
EP3778607A1 (en) 2021-02-17
AU2020204418A1 (en) 2020-07-23
MA49861A (fr) 2021-05-05
PE20211775A1 (es) 2021-09-08
CN112062778B (zh) 2024-04-19
NZ775526A (en) 2024-05-31
IL277774A (en) 2020-11-30
KR102014326B1 (ko) 2019-08-26
CO2017011038A2 (es) 2018-02-09
US20210246129A1 (en) 2021-08-12
MX2017016344A (es) 2018-05-02
JP7266630B2 (ja) 2023-04-28
ES2764497T3 (es) 2020-06-03
DK3317284T3 (da) 2020-01-13
UA121678C2 (uk) 2020-07-10
US10851091B2 (en) 2020-12-01
PH12020551315A1 (en) 2021-07-05
RU2018103454A (ru) 2019-08-05
PH12017502425A1 (en) 2018-07-02
CN112062778A (zh) 2020-12-11
HK1253003A1 (zh) 2019-06-06
PL3567045T3 (pl) 2022-04-19
JP2019178135A (ja) 2019-10-17
IL272277B (en) 2021-01-31
PE20181021A1 (es) 2018-06-27
HRP20192349T1 (hr) 2020-03-20
CN107873032B (zh) 2020-07-17
CN111909173A (zh) 2020-11-10
US20190263793A1 (en) 2019-08-29
EP3317284A1 (en) 2018-05-09
EP3317284B1 (en) 2019-10-30
AR105238A1 (es) 2017-09-20
TW202108592A (zh) 2021-03-01
CN107873032A (zh) 2018-04-03
EP4585597A1 (en) 2025-07-16
FIC20253008I1 (fi) 2025-09-22
CN112047960B (zh) 2024-08-02
TWI698440B (zh) 2020-07-11
US20180127404A1 (en) 2018-05-10
SI3317284T1 (sl) 2020-02-28
AU2016287463A1 (en) 2017-10-26
TW201712020A (zh) 2017-04-01

Similar Documents

Publication Publication Date Title
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2021009673A (es) Moduladores de ror-gamma.
CL2019001993A1 (es) Inhibidores selectivos de jak1.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
UY37098A (es) Moduladores de ror-gamma
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2019002810A1 (es) Compuestos inhibidores de ask1 y usos de los mismos.
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
CO2017001994A2 (es) Compuestos activos hacia bromodominios
BR112018006259A2 (pt) &#34;adjunto compressível com estruturas de suporte intermediárias&#34;
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
MX2017014375A (es) Moduladores del ccr2.
CL2013003160A1 (es) Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros.
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.